Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 449 | 96 | 341 |
| Samples | 411 | 84 | 319 |
| Peptides | 331 | 67 | 264 |
Function
TAF4 · TATA-box binding protein associated factor 4
Initiation of transcription by RNA polymerase II requires the activities of more than 70 polypeptides. The protein that coordinates these activities is transcription factor IID (TFIID), which binds to the core promoter to position the polymerase properly, serves as the scaffold for assembly of the remainder of the transcription complex, and acts as a channel for regulatory signals. TFIID is composed of the TATA-binding protein (TBP) and a group of evolutionarily conserved proteins known as TBP-associated factors or TAFs. TAFs may participate in basal transcription, serve as coactivators, function in promoter recognition or modify general transcription factors (GTFs) to facilitate complex assembly and transcription initiation. This gene encodes one of the larger subunits of TFIID that has been shown to potentiate transcriptional activation by retinoic acid, thyroid hormone and vitamin D3 receptors. In addition, this subunit interacts with the transcription factor CREB, which has a glutamine-rich activation domain, and binds to other proteins containing glutamine-rich regions. Aberrant binding to this subunit by proteins with expanded polyglutamine regions has been suggested as one of the pathogenetic mechanisms underlying a group of neurodegenerative disorders referred to as polyglutamine diseases. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000252996 | O00268 | 449 | 331 |
Gene Properties
Recurrent Mutations
All 331 amino-acid changes on canonical ENST00000252996 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in TAF4 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in TAF4 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Cell Non-Hodgkins Lymphoma | 3/26 12% | 0/0 0% |
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Endometrial Carcinoma | 5/42 12% | 21/612 3% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Colorectal Carcinoma | 14/143 10% | 65/3239 2% |
| Melanoma | 8/210 4% | 40/1899 2% |
| Gastric Carcinoma | 8/74 11% | 33/1809 2% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Hodgkins Lymphoma | 0/16 0% | 2/122 2% |
| Non-Small Cell Lung Carcinoma | 8/304 3% | 15/1390 1% |
| Cervical Carcinoma | 1/35 3% | 5/422 1% |
| Thyroid Gland Carcinoma | 3/45 7% | 18/1592 1% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 9/810 1% |
| Biliary Tract Carcinoma | 0/54 0% | 11/950 1% |
| Bladder Carcinoma | 2/58 3% | 8/956 1% |
| Rhabdomyosarcoma | 0/33 0% | 2/171 1% |
| Osteosarcoma | 2/45 4% | 0/166 0% |
| Other Solid Cancers | 1/94 1% | 11/1515 1% |
| Ovarian Carcinoma | 1/109 1% | 6/998 1% |
| Glioma | 0/52 0% | 13/2127 1% |
| Plasma Cell Myeloma | 1/44 2% | 1/305 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 4/752 1% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Other Sarcomas | 2/69 3% | 2/699 0% |
| Esophageal Carcinoma | 0/23 0% | 4/769 1% |
| Head and Neck Carcinoma | 2/85 2% | 6/1574 0% |
| Hepatocellular Carcinoma | 0/46 0% | 10/2210 0% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Pancreatic Carcinoma | 2/89 2% | 5/1611 0% |
Mutation Distribution
Where TAF4 is mutated · all tissues, split by cell line vs tissue
How many mutations in TAF4 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 449 mutations in TAF4
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|